Zoe BollingerDec 18, 2014Myriad Loses Appeal, Has Gene Patents invalidated0 Comments Myriad Loses Appeals Court Bid to Block Breast Cancer Tests - Bloomberg Myriad Genetics Inc. can’t block competitors’ DNA tests to determine risk for breast and ovarian cancer after a U.S. appeals court said three patents on the tests never should have been issued.